Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
ACS Med Chem Lett ; 14(7): 943-948, 2023 Jul 13.
Article in English | MEDLINE | ID: mdl-37465305

ABSTRACT

We describe N-alkyl carbamoylimidazoles as readily available and highly versatile synthons for synthesizing urea-based prostate-specific membrane antigen (PSMA) inhibitors. Urea formation proceeded in high yields (>80%) at room temperature under aqueous conditions. All novel compounds were tested for their PSMA inhibitory potency in a cell-based radiometric binding assay. Compound 17 was identified as a novel high-affinity PSMA inhibitor (IC50 = 0.013 µM) suitable for developing an 18F-labeled radioligand for PET imaging of PSMA in prostate cancer.

2.
Bioorg Med Chem Lett ; 90: 129345, 2023 06 15.
Article in English | MEDLINE | ID: mdl-37217023

ABSTRACT

We have prepared and tested radioligand [18F]ONO-8430506 ([18F]8) as a novel ATX PET imaging agent derived from highly potent ATX inhibitor ONO-8430506. Radioligand [18F]8 could be prepared in good and reproducible radiochemical yields of 35 ± 5% (n = 6) using late-stage radiofluorination chemistry. ATX binding analysis showed that 9-benzyl tetrahydro-b-carboline 8 has about five times better inhibitory potency than clinical candidate GLPG1690 and somewhat less inhibitory potency than ATX inhibitor PRIMATX. The binding mode for compound 8 inside the catalytic pocket of ATX using computational modelling and docking protocols revealed that compound 8 resembled a comparable binding mode to that of ATX inhibitor GLPG1690. However, PET imaging studies with radioligand [18F]8 showed only relatively low tumour uptake and retention (SUV60min 0.21 ± 0.03) in the tested 8305C human thyroid tumour model reaching a tumour-to-muscle ratio of âˆ¼ 2.2 after 60 min.


Subject(s)
Neoplasms , Humans , Positron-Emission Tomography , Carbolines , Radiopharmaceuticals/pharmacology , Fluorine Radioisotopes/chemistry
3.
Int J Mol Sci ; 21(23)2020 Dec 05.
Article in English | MEDLINE | ID: mdl-33291475

ABSTRACT

The efficacy of paclitaxel (PTX) is limited due to its poor solubility, poor bioavailability, and acquired drug resistance mechanisms. Designing paclitaxel prodrugs can improve its anticancer activity and enable formulation of nanoparticles. Overall, the aim of this work is to improve the potency of paclitaxel with prodrug synthesis, nanoparticle formation, and synergistic formulation with lapatinib. Specifically, we improve potency of paclitaxel by conjugating it to α-tocopherol (vitamin E) to produce a hydrophobic prodrug (Pro); this increase in potency is indicated by the 8-fold decrease in half maximal inhibitory concentration (IC50) concentration in ovarian cancer cell line, OVCA-432, used as a model system. The efficacy of the paclitaxel prodrug was further enhanced by encapsulation into pH-labile nanoparticles using Flash NanoPrecipitation (FNP), a rapid, polymer directed self-assembly method. There was an 1100-fold decrease in IC50 concentration upon formulating the prodrug into nanoparticles. Notably, the prodrug formulations were 5-fold more potent than paclitaxel nanoparticles. Finally, the cytotoxic effects were further enhanced by co-encapsulating the prodrug with lapatinib (LAP). Formulating the drug combination resulted in synergistic interactions as indicated by the combination index (CI) of 0.51. Overall, these results demonstrate this prodrug combined with nanoparticle formulation and combination therapy is a promising approach for enhancing paclitaxel potency.


Subject(s)
Drug Carriers/chemistry , Drug Delivery Systems , Nanoparticles/chemistry , Paclitaxel/administration & dosage , Polymers/chemistry , Prodrugs/administration & dosage , Antineoplastic Agents, Phytogenic/administration & dosage , Antineoplastic Agents, Phytogenic/chemistry , Biological Availability , Cell Line, Tumor , Cell Survival/drug effects , Dose-Response Relationship, Drug , Drug Compounding , Drug Liberation , Drug Synergism , Humans , Hydrogen-Ion Concentration , Molecular Structure , Paclitaxel/chemistry , Prodrugs/chemistry
4.
Chem Commun (Camb) ; 49(72): 7926-8, 2013 Sep 18.
Article in English | MEDLINE | ID: mdl-23900491

ABSTRACT

IBX facilitated the reaction of ß-enamino esters with allylic alcohols affording a direct, one-pot and metal free synthesis of functionalized pyridines including 2-substituted nicotinic acids, densely substituted pyridines and precursors of azafluorenones. The methodology also afforded the racemic pyridine core of cyclothiazomycin.

5.
Acta Crystallogr Sect E Struct Rep Online ; 65(Pt 9): o2159, 2009 Aug 15.
Article in English | MEDLINE | ID: mdl-21577567

ABSTRACT

The analysis of the title chiral auxiliary compound, C(13)H(15)NOS(2), has enabled the determination of the absolute configuration at the benzyl-bearing ring C atom as S. In the crystal structure, mol-ecules aggregate into helical chains along the b axis via C-H⋯O contacts.

SELECTION OF CITATIONS
SEARCH DETAIL
...